Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 12.00 |
|---|---|
| High | 12.30 |
| Low | 12.00 |
| Bid | 12.00 |
| Offer | 12.60 |
| Previous close | 11.90 |
| Average volume | 291.40 |
|---|---|
| Shares outstanding | 314.36m |
| Free float | 156.08m |
| P/E (TTM) | 894.07 |
| Market cap | 4.64bn USD |
| EPS (TTM) | 0.0165 USD |
Data delayed at least 15 minutes, as of Feb 06 2026 14:25 GMT.
More ▼
- Amneal Pharmaceuticals Added to S&P SmallCap 600® Index
- Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026
- Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®
- Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals
- Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease
- Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol
- Amneal to Participate in Upcoming Investor Conferences
- Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%
- Amneal Receives U.S. FDA Approval for Iohexol Injection
- Amneal Reports Third Quarter 2025 Financial Results
More ▼
